Monoaminergic, ion channel and enzyme inhibitory activities of natural aporphines, their analogues and derivatives

Natural Product Communications

Volumn 3, Issue 4, 2008, Pages 643-653

  Cassels, Bruce K ^a   Asencio, Marcelo ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Aporphine alkaloids; Dopamine; Enzymes; Ion channels; Norepinephrine; Semi synthetic derivatives; Serotonin

Indexed keywords

ANONAINE; APOREINE; APORPHINE DERIVATIVE; BOLDINE; BULBOCAPNINE; GLAUCINE; NANTENINE; NORUSHINSUNINE; PUKATEINE; UNCLASSIFIED DRUG;

BINDING AFFINITY; BIOSYNTHESIS; CHOLINERGIC ACTIVITY; DOPAMINERGIC ACTIVITY; DRUG ACTIVITY; ENZYME ACTIVITY; NONHUMAN; REVIEW;

EID: 70349399159     PISSN: 1934578X     EISSN: 15559475     Source Type: Journal    
DOI: 10.1177/1934578x0800300422     Document Type: Review

References (87)

1. Shamma M. (1972) Isoquinoline Alkaloids: Chemistry and Pharmacology. Academic Press, New York, 194-228.
2. Brown GM, Hall LH. (1977) The crystal structures, molecular structures, and absolute configurations of the hydrobromides of the aporphine alkaloids leukoxine and isoboldine. Acta Crystallographica, B33, 2051-2057.
3. Asencio M, Cassels BK, Manríquez V, Boys D. (1996) Structure of (S)-1,10.dimethoxy-2,9-dihydroxyaporphinium chloride (boldine hydrochloride). Acta Crystallographica, C52, 1581-1583.
4. Woo SH, Sun NJ, Cassady JM, Snapka RM. (1999) Topoisomerase II inhibition by aporphine alkaloids. Biochemical Pharmacology, 57, 1141-1145.
5. Mathiessen A, Wright CRA. (1869) Researches into the chemical constitution of narcotine and of its products of decomposition. Proceedings of the Royal Society, B17, 455-462.
6. Zhang A, Neumeyer JL, Baldessarini RJ. (2007) Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders. Chemical Reviews, 107, 274-302.
7. Zhang A, Zhang Y, Branfman AR, Neumeyer JL, Baldessarini RJ. (2007) Advances in development of dopaminergic aporphinoids. Journal of Medicinal Chemistry, 50, 171-181.
8. Ernst EM, Smelik K. (1966) Site of action of dopamine and apomorphine on compulsive gnawing behaviour in rats. Experientia, 22, 837-838.
9. Neumeyer JL, Neustadt BR, Weinhardt KK. (1970) Aporphines. V. Total synthesis of (plus or minus)-apomorphine. Journal of Pharmaceutical Sciences, 59, 1850-1852.
10. Neumeyer JL. (1985) Synthesis and structure-activity relationships of aporphines as dopamine receptor agonists and antagonists. In The Chemistry and Biology of Isoquinoline Alkaloids. Phillipson JD, Roberts MR, Zenk MH (Eds). Springer-Verlag, Berlin, Germany, 146-170.
11. Henry GW. (1932) Catatonia in animals: experimental studies on the effect of bulbocapnine and other drugs. American Journal of Psychiatry, 88, 757-793.
12. González-Vegas JA, Wolstencroft JH. (1971) Antagonism of noradrenaline and dopamine inhibition of brain-stem neurones by bulbocapnine. Journal of Physiology, 214, 16P-17P.
13. Zetler G. (1988) Neuroleptic-like, anticonvulsant and antinociceptive effects of apomorphine alkaloids: bulbocapnine, corytuberine, boldine and glaucine. Archives Internationales de Pharmacodynamie et de Thérapie, 296, 255-281.
14. Asencio M, Delaquerrière B, Cassels BK, Speisky H, Comoy E, Protais P. (1999) Biochemical and behavioral effects of boldine and glaucine on dopamine systems. Pharmacology Biochemistry & Behavior, 62, 7-13.
15. Sobarzo-Sánchez EM, Arbaoui J, Protais P, Cassels BK. (2000) Halogenated boldine derivatives with enhanced monoamine receptor selectivity. Journal of Natural Products, 63, 480-484.
16. Loghin F, Chagraoui A, Asencio M, Comoy E, Speisky H, Cassels BK, Protais P. (2003) Effects of some antioxidative aporphine derivatives on striatal dopaminergic transmission and on MPTP-induced striatal dopamine depletion in B6CBA mice. European Journal of Pharmaceutical Sciences, 18, 133-140.
17. Asencio M, Hurtado-Guzmán C, López JJ, Cassels BK, Protais P, Chagraoui A. (2005) Structure-affinity relationships of halogenated predicentrine and glaucine derivatives at D1 and D2 dopaminergic receptors. Bioorganic & Medicinal Chemistry, 13, 3699-3704.
18. Dajas-Bailador FA, Asencio M, Bonilla C, Scorza MC, Etcheverry C, Reyes-Parada M, Silveira R, Protais P, Russell G, Cassels BK, Dajas F. (1999) Dopaminergic pharmacology and antioxidant properties of pukateine, a natural product lead for the design of agents increasing dopamine neurotransmission. General Pharmacology, 32, 373-379. (Pubitemid 29146052)
19. Saum WR, Groat WC. (1972) Antagonism by bulbocapnine of adrenergic inhibition in parasympathetic ganglia in the urinary bladder. Brain Research, 37, 340-344.
20. Ilhan M, Long JP, Cannon JG. (1975) Bulbocapnine's ability to antagonize the adrenergic inhibitory action of dopamine and analogs. European Journal of Pharmacology, 33, 13-18.
21. Zhang YH, Shin JS, Lee SS, Lee MK. (1997) Inhibition of tyrosine hydroxylase by bulbocapnine. Planta Medica, 63, 362-363.
22. Shin JS, Kim KT, Lee MK. (1998) Inhibitory effects of bulbocapnine on dopamine biosynthesis in PC12 cells. Neuroscience Letters, 244, 161-164. (Pubitemid 28226316)
23. Kohli JD, Glock D, Goldberg LI. (1986) Bulbocapnine is not a selective DA1 receptor antagonist. Journal of Pharmacy and Pharmacology, 38, 401-402. (Pubitemid 16102037)
24. Speisky H, Cassels BK, Sanhueza V, Nieto S, Valenzuela A, Núñez-Vergara LJ. (1993) Determination of boldine in plasma by highperformance liquid chromatography. Journal of Chromatography - Biomedical Applications, 612, 315-319.
25. Jiménez I, Speisky H. (2000) Biological disposition of boldine: in vitro and in vivo studies. Phytotherapy Research, 14, 254-260. (Pubitemid 30410053)
26. Bhakuni DS, Tewari S, Kapil RS. (1977) Biosynthesis of boldine. Journal of the Chemical Society, Perkin Transactions 1, 706-709.
27. Tschesche R, Welzel P, Moll R, Legler G. (1964) Über 2 Alkaloide aus der Rinde von Symplocos celastrinea Mart. Tetrahedron, 20, 1435-1438.
28. Asencio M, Cassels BK, Speisky H. (1993) The methylation of boldine with diazomethane. Boletín de la Sociedad Chilena de Química, 38, 331-334.
29. Sobarzo-Sánchez EM, Cassels BK, Saitz-Barría C, Jullian C. (2001) Oxazine- and oxazole-fused derivatives of the alkaloid boldine and their complete structural and spectral assignment by HMQC and HMBC experiments. Magnetic Resonance in Chemistry, 39, 361-366.
30. Asencio M. (2002) Chemistry of aporphinoids and relationships between their structures and their antioxidant and monoaminergic activities. PhD Thesis, University of Chile.
31. Petkov V, Todorov S, Georgiev V, Petkova B, Donev N. (1979) Pharmacological studies of a group of semi-synthetic structural analogues of glaucine. Acta Physiologica et Pharmacologica Bulgarica, 5, 3-12. (Pubitemid 10067515)
32. Orallo F, Fernández Alzueta A, Loza MI, Vivas N, Badía A, Campos M, Honrubia MA, Cadavid MI. (1993) Study of the mechanism of the relaxant action of (+)-glaucine in rat vas deferens. British Journal of Pharmacology, 110, 943-948.
33. Orallo F, Fernández Alzueta A, Campos-Toimil M, Calleja JM. (1995) Study of the in vivo and in vitro cardiovascular effects of (+)-glaucine and N-carbethoxysecoglaucine in rats. British Journal of Pharmacology, 114, 1419-1427.
34. De las Heras B, Ríos JL, Martínez-Mir I, Rubio E. (1990) A study of the adrenergic activity of the alkaloids boldine and glaucine. Die Pharmazie, 454, 443-444.
35. 2+ channels. European Journal of Pharmacology, 231, 165-174.
36. Ivorra MD, Lugnier C, Schott C, Catret M, Noguera MA, Anselmi E, D'Ocon O. (1992) Multiple actions of glaucine on cyclic nucleotide phosphodiesterases, alpha 1-adrenoceptor and benzothiazepine binding site at the calcium channel. British Journal of Pharmacology, 106, 387-394.
37. Loza I, Orallo F, Verde I, Gil-Longo J, Cadavid I, Calleja JM. (1995) A study of glaucine-induced relaxation of rat aorta. Planta Medica, 59, 229-231. (Pubitemid 23168769)
38. Ivorra MD, Martínez F, Serrano A, D'Ocon P. (1993) Different mechanism of relaxation induced by aporphine alkaloids in rat uterus. Journal of Pharmacy and Pharmacology, 45, 439-443.
39. Chuliá S, Moreau J, Naline E, Noguera MA, Ivorra MD, D'Ocón P, Advenier C. (1996) The effect of S-(+)-boldine on the alpha 1-adrenoceptor of the guinea-pig aorta. British Journal of Pharmacology, 119, 1305-1312.
40. Madrero Y, Elorriaga M, Martínez S, Noguera MA, Cassels BK, D'Ocón P, Ivorra MD. (1996) A possible structural determinant of selectivity of boldine and derivatives for the alpha 1-adrenoceptor subtype. British Journal of Pharmacology, 119, 1563-1568.
41. Fabeiro P, Álvarez E, Orallo F. (1999) Comparative study of the vasodilator effects of (+)-boldine, an alkaloid isolated from Peumus boldus, in rat small mesenteric arteries and rat aorta. Methods and Findings in Experimental and Clinical Pharmacology, 21 (Supplement A), 73.
42. 2- adrenergic receptor blocking activity of (+)-boldine in normotensive rats. Methods and Findings in Experimental and Clinical Pharmacology, 22, 517.
43. 2-adrenoceptor subtypes and in vitro cardiovascular actions of (+)-boldine. European Journal of Pharmacology, 443, 151-168.
44. 1A-adrenoceptors in rat cerebral cortex. Life Sciences, 64, 1205-1214.
45. 2-boldine, an antagonist of alpha1A and alpha1B adrenoceptors without affinity for the alpha1D subtype: structral requirements for aporphines at alpha1-adrenoceptor subtypes. Planta Medica, 71, 897-903.
46. Fuller BB, Drake MA, Spaulding DT, Chaudhry F. (2000) Downregulation of tyrosinase activity in human melanocyte cell cultures by yohimbine. Journal of Investigative Dermatology, 115, 268-276.
47. Mas-Chamberlin C, Peschard O, Leroux R, Mondon P, Lamy F, Lintner K. (2004) Di-acetyl-nor-aporphines: novel molecules and novel mechanism to inhibit melanogenesis. SÖFW-Journal, 130, 2-10.
48. Teng CM, Yu SM, Ko FN, Chen CC, Huang YL, Huang TF. (1991) Dicentrine, a natural vascular alpha 1-adrenoceptor antagonist, isolated from Lindera megaphylla. British Journal of Pharmacology, 104, 651-656.
49. Yu SM, Hsu SY, Ko FN, Chen CC, Huang YL, Huang TF, Teng CM. (1992) Haemodynamic effects of dicentrine, a novel alpha 1-adrenoceptor antagonist: comparison with prazosin in spontaneously hypertensive and normotensive Wistar-Kyoto rats. British Journal of Pharmacology, 106, 797-801.
50. Su MJ, Nieh YC, Huang HW, Chen CC. (1994) Dicentrine, an alpha-adrenoceptor antagonist with sodium and potassium channel blocking activities. Naunyn-Schmiedebergs Archives of Pharmacology, 349, 42-49. (Pubitemid 2011427)
51. Mustafa MR, Achike FI. (2000) Dicentrine is preferentially antagonistic to rat aortic than splenic alpha 1-adrenoceptor stimulation. Acta Pharmacologica Sinica, 21, 1165-1168.
52. Orallo F, Alzueta AF. (2001) Preliminary study of the vasorelaxant effects of (+)-nantenine, an alkaloid isolated from Platycapnos spicata, in rat aorta. Planta Medica, 67, 800-806.
53. + in rat vas deferens. European Journal of Pharmacology, 470, 37-43.
54. Orallo F. (2003) Pharmacological effects of (+)-nantenine, an alkaloid isolated from Platycapnos spicata, in several rat isolated tissues. Planta Medica, 69, 135-142.
55. Tsuchida H, Ohizumi Y. (2003) (+)-Nantenine isolated from Nandina domestica Thunb. inhibits adrenergic pressor responses in pithed rats. European Journal of Pharmacology, 477, 53-58.
56. Orallo F. (2004) Acute cardiovascular effects of (+)-nantenine, an alkaloid isolated from Platycapnos spicata, in anaesthetised normotensive rats. Planta Medica, 70, 117-126.
57. Guh J-H, Ko F-N, Yu S-M, Wu Y-C, Teng C-M. (1995) Pharmacological evaluation of N-metylactinodaphnine, a new vascular α-adrenoceptor antagonist, isolated from Illigera luzonensis. European Journal of Pharmacology, 279, 33-41.
58. 1-adrenoceptor antagonist in rat thoracic aorta. Japanese Journal of Pharmacology, 73, 207-214.
59. Sotníková R, Kettmann V, Kostálová D, Táborská E. (1997) Relaxant properties of some aporphine alkaloids from Mahonia aquifolium. Methods and Findings in Experimental and Clinical Pharmacology, 19, 589-597.
60. Chuliá S, Noguera MA, Ivorra MD, Cortes D, D'Ocón MP. (1995) Vasodilator effects of liriodenine and norushinsunine, two aporphine alkaloids isolated from Annona cherimolia, in rat aorta. Pharmacology, 50, 380-387.
61. Chuliá S, Ivorra MD, Cavé A, Cortés D, Noguera MA, D'Ocón P. (1995) Relaxant activity of three aporphine alkaloids from Annona cherimolia on isolated aorta of rat. Journal of Pharmacy and Pharmacology, 47, 647-650.
62. 1-adrenoceptor subtypes. Planta Medica, 70, 603-609.
63. Shoji N, Umeyama A, Takemoto T., Ohizumi Y. (1984) Serotonergic receptor antagonist from Nandina domestica Thunberg. Journal of Pharmaceutical Sciences, 73, 568-570. (Pubitemid 14134344)
64. Indra B, Tadano T, Nakagawasai O, Arai Y, Yasuhara H, Ohizumi Y, Kisara K. (2002) Suppressive effect of nantenine, isolated from Nandina domestica Thunberg, on the 5-hydroxy-L-tryptophan plus clorgyline-induced head-twitch response in mice. Life Sciences, 70, 2647-2656.
65. Ribeiro RA, Rodríguez de Lores Arnaiz G. (2000) Nantenine and papaverine differentially modify synaptosomal membrane enzymes. Phytomedicine, 7, 313-323.
66. +-p-NPPase activity. Phytomedicine, 8, 107-111.
67. Ribeiro RA, Leite JR. (2003) Nantenine alkaloid presents anticonvulsant effect on two classical animal models. Phytomedicine, 10, 563-568.
68. Fantegrossi WE, Kiessel CL, Leach PT, van Martin C, Karabenick RL, Chen X, Ohizumi Y, Ullrich T, Rice KC, Woods JH. (2004) Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice. Psychopharmacology (Berlin), 173, 270-277.
69. 1A receptors in vitro. Journal of Natural Products, 69, 432-435.
70. Catret M, Ivorra MD, D'Ocón MP, Anselmi E. (1998) The 5-HT and alpha-adrenoceptor effect of four benzylisoquinoline alkaloids on rat aorta. Journal of Pharmacy and Pharmacology, 50, 317-322.
71. Li HL, Zhang RP, Ye HT, Wang H. (2000) Effect of dicentrine on contraction of rat stomach muscle strips. Zhongguo Zhong Yao Za Zhi, 25, 426-428.
72. Indra B, Matsunaga K, Hoshino O, Suzuki M, Ogasawara H, Ishiguro M, Ohizumi Y. (2002) Structure-activity relationship on (±)-nantenine derivatives in antiserotonergic activities in rat aorta. Canadian Journal of Physiology and Pharmacology, 80, 198-204.
73. 1D-adrenoceptor antagonist activity. European Journal of Pharmacology, 437, 173-178.
74. 1-adrenoceptors. European Journal of Pharmacology, 445, 21-29.
75. Iturriaga-Vásquez P, Pérez EG, Slater EY, Bermúdez I, Cassels BK. (2007) Aporphine metho salts as neuronal nicotinic acetylcholine receptor blockers. Bioorganic & Medicinal Chemistry, 15, 3368-3372.
76. Erhardt PA, Soine TO. (1975) Stereochemical preferences for curaremimetic neuromuscular junction blockade. I. Enantiomeric monoquaternary amines as probes. Journal of Pharmaceutical Sciences, 64, 53-62.
77. Yu SM, Lee SS, Hou YS, Chen CM. (1994) Mechanisms of vasorelaxation induced by N-allylsecoboldine in rat thoracic aorta. Naunyn-Schmiedebergs Archives of Pharmacology, 349, 637-643.
78. 1-adrenoceptor antagonists on human hyperplastic prostate. European Journal of Pharmacology, 374, 503-510.
79. Cassels BK, Asencio M, Conget P, Speisky H, Videla LA, Lissi EA. (1995) Structure-antioxidative activity relationships in benzylisoquinoline alkaloids. Pharmacological Research, 31, 103-107.
80. Frantz S. (2005) Playing dirty. Nature, 437, 942-943.
81. van der Schyf CJ, Geldenhuys WJ, Youdim MB. (2006) Multifunctional drugs with different CNS targets for neuropsychiatric disorders. Journal of Neurochemistry, 99, 1033-1048.
82. Roth BL, Sheffler DJ, Kroeze WK. (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nature Reviews in Drug Discovery, 3, 353-359.
83. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. Journal of Neurochemistry, 76, 1521-1531.
84. 1A agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology, 49, 996-1006.
85. 1A agonist properties. Neuropsychopharmacology, 31, 1869-1879.
86. 2 receptor blockade. Neuropsychopharmacology, 31, 1900-1909.
87. 1Aagonist with antipsychotic- and antiparkinsonian-like properties. Neuropharmacology, 51, 129-140.